TMDX

TransMedics Group, Inc. [TMDX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TMDX Stock Summary

Top 10 Correlated ETFs

TMDX

Top 10 Correlated Stocks

TMDX

In the News

TMDX Financial details

Company Rating
-
Market Cap
3B
Income
-25.03M
Revenue
241.62M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
584
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-78.11
Forward P/E
-
PEG
21
P/S
14.58
P/B
22.1
P/C
-
P/FCF
-118.69
Quick Ratio
9.93
Current Ratio
10.93
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
-37.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-20.07%
Revenue last 5Y
59.23%
Revenue Q/Q
22.19%
EPS Q/Q
-115.38%
-
-
-
-
SMA20
13.04%
SMA50
4%
SMA100
-2.99%
Inst Own
-
Inst Trans
-
ROA
-5%
ROE
-22%
ROC
-0.06%
Gross Margin
66%
Oper. Margin
-20%
Profit Margin
-19%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
36.42-99.63
52W High
+37.63%
52W Low
+278.48%
RSI
71
Rel Volume
1.8
Avg Volume
696.83K
Volume
1.26M
Perf Week
13.98%
Perf Month
11.42%
Perf Quarter
14.76%
Perf Half Y
51.07%
-
-
-
-
Beta
2.001
-
-
Volatility
2.54%, 7.93%
Prev Close
1.44%
Price
136.2522
Change
4.45%

Something similar

Top by Market Cap
GOOGL
FXAIX
V
MIX.JO
LLY
Top Correlated ETFs
MID
SDEM
LDAG.L
DVYE
IEMS.L
Top Correlated Stocks
DIBS
DOV
TREL-B.ST
NOVT
ARLO
Similar Market Cap
ORBTEXP.NS
OUT1V.HE
LCIAX
PFPMX
BANC

Company Profile

Healthcare Medical - Devices
  • Volume Average 696.83K
  • Market Capitalization 3B
  • Employee 584
  • CEO Dr. Waleed H. Hassanein M.D.
  • Headquarters Andover,MA,US
  • IPO Date 2019-05-02
  • Website https://www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.